IMP vs NIMP: understanding the 5 critical differences in EU clinical trials
If you have ever worked on an EU-based clinical trial and found yourself uncertain about whether a particular medicinal product should be classified as an IMP or a NIMP, you are not alone. The distinction between an investigational medicinal product (IMP) and a non-investigational medicinal product (NIMP) is one of the most frequently misunderstood concepts in EU clinical trial regulation, and getting it wrong can have significant consequences: from regulatory non-compliance and delayed approvals to unnecessary safety reporting burdens and unanticipated costs.
This post is the fifth in our series on investigational products in clinical trials. If you have not already read our main guide, What is an investigational medicinal product? 7 essential ICH GCP rules, that is the place to start before diving into the EU-specific distinctions covered here.
Understanding the IMP vs NIMP question requires more than knowing two definitions. It requires understanding the regulatory framework that created those definitions, the way that framework has evolved under the EU Clinical Trials Regulation (CTR) No. 536/2014, and the practical implications for everyone involved in an EU clinical trial, from sponsors and investigators to CRAs and site pharmacists. Whether you are preparing for ICH GCP training, working toward ICH GCP certification, or managing a live EU trial, this guide will give you the clarity you need.
What is an IMP in EU clinical trials?
An investigational medicinal product (IMP) is, as defined under EU Clinical Trials Regulation No. 536/2014, a medicinal product being tested or used as a reference, including as a placebo, in a clinical trial. This definition is functionally identical to the ICH GCP E6(R3) definition of an investigational product, which you can explore in detail in our guide, What are the principles of ICH GCP: the 2026 E6(R3) guide?
In practical terms, a product qualifies as an IMP in an EU trial when it meets one or more of the following criteria: it is the novel compound being evaluated for safety and/or efficacy, it is a licensed medicine being studied in a new indication or formulation not covered by its authorization, it is a placebo used as a control in a blinded or unblinded trial, or it is an active comparator product being used as a reference product against which the test product is being measured.
The IMP is the product that is at the scientific and regulatory heart of the trial. Its entire development program, from manufacture and release to packaging, labeling, distribution, accountability, and return or destruction, is subject to the strictest requirements under the EU CTR and the applicable Good Manufacturing Practice (GMP) guidelines, specifically EudraLex Volume 4, Annex 13, which governs the manufacture of investigational medicinal products in the EU.
What is a NIMP in EU clinical trials?
A non-investigational medicinal product (NIMP) is a medicinal product that is used in a clinical trial as described in the protocol, but that is not itself an IMP. In other words, it is a medicinal product that supports the conduct of the trial without being the product under investigation.
Under the older EU regulatory framework, the Clinical Trials Directive 2001/20/EC, the NIMP was the standard term. The EU Commission published detailed guidance on the IMP vs NIMP distinction, specifically the European Commission guidance on investigational medicinal products and non-investigational medicinal products, which helped trial teams navigate classification questions in practice.
However, as we will discuss in the next section, the EU CTR 536/2014 replaced the term NIMP with a new concept: the auxiliary medicinal product (AxMP). Understanding this terminological shift is essential for anyone working in EU clinical trials today, and it is a topic that is increasingly examined in Good Clinical Practice training programs.
The regulatory evolution: from NIMP to AxMP under EU CTR 536/2014
One of the most significant terminology changes introduced by the EU Clinical Trials Regulation No. 536/2014, which became applicable from January 31, 2022, was the formal replacement of the term “non-investigational medicinal product” (NIMP) with “auxiliary medicinal product” (AxMP, sometimes abbreviated as AMP).
Under Article 2(10) of the EU CTR 536/2014, an auxiliary medicinal product is defined as a medicinal product used for the needs of a clinical trial as described in the protocol, but not as an investigational medicinal product. This definition captures the same functional concept as the former NIMP: a product that is present in the trial, specified in the protocol, but is not under investigation itself.
The change from NIMP to AxMP was not merely cosmetic. It was intended to bring greater regulatory clarity and to harmonize the EU framework with evolving scientific standards. The Clinical Trials Coordination and Advisory Group (CTAG) has issued updated recommendations on the use of AxMPs, providing additional practical guidance on classification decisions that had previously led to inconsistent treatment by different national competent authorities. The CTAG recommendations on auxiliary medicinal products are now the primary authoritative reference for EU trial teams working through IMP vs NIMP (AxMP) classification questions.
It is important to note that the UK, following Brexit, has retained the use of the term NIMP in its own clinical trials legislation, the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended by the 2025 regulations. This means that multinational trials running in both the EU and the UK may need to manage two parallel terminologies for the same regulatory concept, which makes a strong grasp of both the IMP vs NIMP and the IMP vs AxMP distinction especially important for sponsor and CRO teams.
5 critical differences between IMP and NIMP (AxMP) in EU clinical trials
Understanding the IMP vs NIMP distinction at a conceptual level is only the beginning. The real-world significance of the classification lies in the different regulatory requirements that apply to each. Here are the five most critical differences every EU clinical trial professional needs to know.
1. Regulatory definition and legal basis
The IMP is defined by its role in the trial hypothesis. For a product being tested, used as a comparator, or used as a placebo, the trial is designed to measure or describe its performance, safety, and effects. The NIMP (or AxMP under the EU CTR) is defined by exclusion: it is everything that is a medicinal product, is in the trial, is specified in the protocol, but is not an IMP.
This definitional asymmetry is intentional. It places the heaviest regulatory burden on the product that is under scientific scrutiny and allows for proportionate treatment of products that are present for supportive or enabling purposes. The classification decision must be made by the sponsor and documented in the trial protocol and the IMP dossier submitted to the CTIS portal.
Classification errors at this stage can have cascading consequences throughout the trial. A product misclassified as a NIMP when it should be an IMP may be subject to inadequate GMP controls, insufficient labeling, and incomplete pharmacovigilance coverage, all of which can be identified during regulatory inspections. For an in-depth understanding of inspection readiness and GCP documentation, see our guide to the key changes between ICH GCP E6 R3 and E6 R2.
2. GMP and manufacturing requirements
IMPs in EU trials must be manufactured in full compliance with the GMP requirements set out in EudraLex Volume 4, Annex 13. This includes formal batch manufacturing records, qualified person (QP) batch certification before release into the clinical supply chain, compliance with environmental controls and validated processes, and a complete quality management system at the manufacturing site.
NIMPs (AxMPs) operate under a different and generally less demanding manufacturing framework. In most cases, an authorized AxMP that is used in its licensed form and within its licensed indications does not require a separate QP certification for clinical trial use. However, if the AxMP is unauthorized in one or more of the countries where the trial is running, or if it has been modified from its authorized form, GMP compliance requirements become significantly more stringent and must be demonstrated in the AxMP dossier submitted through CTIS.
Sponsors should not assume that the lower manufacturing requirements for AxMPs eliminate all GMP obligations. The UK MHRA guidance on NIMPs makes clear that all NIMPs, regardless of authorization status, must be manufactured or assembled in accordance with GMP principles applicable under the relevant clinical trials legislation. An AxMP that is prepared or modified specifically for trial use, for example, a reconstituted rescue medication prepared at the site, may require GMP-compliant manufacturing evidence to be submitted with the trial application.
3. CTIS registration and dossier requirements
Under the EU CTR 536/2014, all clinical trial applications must be submitted through the Clinical Trials Information System (CTIS), the centralized EU portal managed by the European Medicines Agency. Both IMPs and AxMPs must be registered in CTIS, but the documentation requirements differ substantially.
For the IMP, a full or simplified IMP dossier (IMPD) must be submitted. The IMPD contains detailed information on the quality, manufacture, and non-clinical and clinical data supporting the product’s use in the trial. For an IMP that already has marketing authorization in the EU and is used within its authorized conditions, a simplified IMPD is generally acceptable.
For AxMPs, a separate Auxiliary Medicinal Product Dossier (AxMPD) is submitted. The AxMPD contains information on the quality and safety of the AxMP, its proposed labeling, and evidence of GMP compliance. For authorized AxMPs used without modification, a simplified AxMPD is accepted. In addition, IMPs and AxMPs that do not hold an EU marketing authorization must be registered in the extended EudraVigilance Medicinal Product Dictionary (XEVMPD) before the trial application can be completed in CTIS.
Concomitant medications, medications that a participant takes that are unrelated to the trial and not specified in the protocol as part of the trial design, are neither IMPs nor AxMPs and do not need to be registered in CTIS. This distinction between an AxMP and a concomitant medication is a practical classification question that trial teams encounter frequently.
4. Labeling requirements
IMP labeling in the EU is subject to detailed requirements set out in Annex 13 of EudraLex Volume 4 and in Article 66 of the EU CTR. Labels on IMPs must include information such as the name and address of the sponsor, the name of the investigator (in some contexts), the trial reference number and protocol code, the product code, the batch number, the IMP name or description and strength, and storage conditions. In blinded trials, labeling must be designed to maintain the blind while still providing sufficient information to allow safe use.
AxMP labeling requirements are considerably less prescriptive. For an authorized AxMP used in its licensed, unmodified form, the existing commercial labeling is generally sufficient, and no additional clinical trial-specific labeling is required. However, where an AxMP is used in a way that differs from its authorization, for example, where it is repackaged for blinding purposes or for kit assembly, additional labeling requirements apply and must be described in the AxMPD.
The EU Commission and the CTAG guidance both acknowledge that labeling requirements for AxMPs represent an area where proportionality is key: the requirement to maintain participant safety is always present, but the regulatory expectation is calibrated to the level of modification and the authorization status of the product involved.
5. Pharmacovigilance and safety reporting obligations
This is arguably the most operationally significant difference between IMP and NIMP (AxMP) classification in EU clinical trials, and it is one of the most tested areas in Good Clinical Practices training and Good Clinical Practices certification programs.
IMPs are subject to full pharmacovigilance obligations under the EU CTR and the ICH E2 guidelines. Any suspected unexpected serious adverse reaction (SUSAR) that is thought to be causally related to the IMP must be reported to the competent authority and ethics committee within defined expedited timelines, 7 days for fatal or life-threatening SUSARs, and 15 days for all others. Aggregate safety data must be included in the Development Safety Update Report (DSUR) submitted annually to the competent authority.
Authorized AxMPs used within their licensed indications are generally not subject to the same expedited SUSAR reporting obligations. Adverse reactions related to an authorized AxMP are instead handled through routine post-marketing pharmacovigilance channels. However, where there is uncertainty about whether an adverse event is related to the IMP or the AxMP, the regulatory expectation is that the event should be assessed and, if necessary, reported as potentially IMP-related. For a full explanation of adverse event classification and reporting obligations, see our guide to adverse event reporting in clinical trials: the essential ICH GCP guide.
Unauthorized AxMPs are treated more similarly to IMPs from a pharmacovigilance perspective: adverse reactions to unauthorized AxMPs may need to be reported through expedited channels, and this should be addressed explicitly in the trial’s pharmacovigilance plan.
What qualifies as a NIMP or AxMP? Categories and practical examples
Regulatory guidance from the European Commission and the CTAG identifies several distinct categories of AxMPs, each with its own practical implications for trial design and regulatory submission.
Rescue medications
Rescue medications, also called escape medications, are AxMPs provided to participants when the IMP does not have satisfactory efficacy, when the effect of the IMP is too great and risks causing an adverse reaction, or to manage an emergency situation that may arise during the trial. A common example is the provision of opioid analgesia as a rescue medication in a trial of a new analgesic compound. The analgesic under investigation is the IMP; the opioid available for breakthrough pain is the AxMP. Sponsors should clearly specify all rescue medications in the protocol and include them in the AxMPD.
Background treatment
Background treatment AxMPs are administered to all trial participants, regardless of randomization group, as part of the established standard of care for the condition under investigation or for a comorbid condition relevant to the trial design. The key distinction between a background treatment AxMP and an IMP is whether the standard of care treatment is part of the trial hypothesis. If the trial is evaluating the additional benefit of a new agent on top of established therapy, and all participants receive that established therapy regardless of randomization, the background therapy is an AxMP. If the standard of care itself is being compared, for example, in a trial that randomizes participants to standard of care plus the new agent versus standard of care alone, then the standard of care treatment becomes an IMP.
This background treatment classification question is particularly frequent in oncology trials, where participants often receive combinations of approved therapies alongside the novel investigational agent. For an understanding of how trial roles and responsibilities interact in these complex scenarios, our guide on how to set up a clinical trial site and our post on principal investigator responsibilities cover these obligations in depth.
Challenge agents
Challenge agents are AxMPs (or sometimes non-medicinal products) administered to participants to elicit a specific physiological response that is necessary before the effect of the IMP can be assessed. A skin prick test with allergen extracts used to confirm eligibility in an allergy trial is a classic example. The allergen extracts are not being evaluated for their own safety or efficacy; they are tools used to confirm participant eligibility or to provoke the response that the IMP is intended to modify.
Diagnostic agents and endpoint tools
Some medicinal products are used in a trial solely as tools to measure a specific clinical endpoint, rather than as treatments for the participants’ condition. PET radiopharmaceuticals administered to measure organ function before and after IMP administration are a well-recognized example. These products are classified as AxMPs when they are not themselves under investigation and when their role is purely to enable measurement of the IMP’s effects.
Why the IMP vs NIMP classification matters in practice
The regulatory stakes of IMP vs NIMP classification go beyond bureaucratic accuracy. Misclassification in either direction carries real operational, financial, and compliance consequences.
Classifying an IMP as a NIMP means the product may not receive the GMP controls, pharmacovigilance oversight, and CTIS registration it requires, creating gaps that competent authorities and inspectors will identify. Classifying an AxMP as an IMP imposes unnecessary GMP documentation, labeling, and safety reporting obligations on a product that does not warrant them, driving up costs and administrative burden for no regulatory benefit.
The financial dimension is also significant. Sponsor organizations bear all costs associated with IMP manufacture, release, labeling, blinding, distribution, accountability, and destruction. These costs can represent a substantial proportion of total trial costs, sometimes reaching 3 to 10% of the overall study budget for complex, blinded multinational trials. AxMP costs, where the product is an authorized medicine used in its licensed form, may fall to the investigational site, the healthcare system, or the participant, depending on what is agreed in the trial protocol and any applicable national reimbursement frameworks.
Getting the IMP vs NIMP classification right from the outset, ideally at the protocol design stage, reduces the risk of post-authorization amendments, avoids regulatory questions during the competent authority review, and supports smooth trial operations. This is precisely why solid Good Clinical Practice training from a structured, ICH-aligned program is so valuable for everyone involved in EU trial design and management.
IMP vs NIMP in the UK: understanding the terminology gap
Since the UK left the EU regulatory system, UK clinical trials are governed by the Medicines for Human Use (Clinical Trials) Regulations 2004, as most recently amended by the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025, which came into force on April 28, 2026.
The UK has retained the terminology of NIMP rather than adopting the EU’s AxMP designation. This means that for a sponsor running a multinational trial with sites in both the EU and the UK, the same category of product will be referred to as an AxMP in EU regulatory submissions and as a NIMP in UK regulatory submissions. The underlying concept is the same; only the label differs.
UK MHRA guidance confirms that NIMPs must be manufactured or assembled in accordance with GMP principles, must have their quality documented in the trial application, and must be listed in a NIMP dossier as part of the clinical trial authorization application. The UK MHRA guidance on non-investigational medicinal products provides the authoritative reference for UK-specific NIMP requirements.
For professionals working in global regulatory affairs, this EU/UK divergence on NIMP vs AxMP is one of several important post-Brexit regulatory differences that need to be tracked and managed. Understanding how to navigate overlapping regulatory frameworks is a core competency examined in ICH GCP certification programs and assessed during regulatory inspections of multinational trials.
Practical implications for investigators and site teams
For investigators, clinical research coordinators, and site pharmacists, the IMP vs NIMP distinction most directly affects how they handle, store, and document the products used in a trial.
When a product is classified as an IMP, site teams must apply the full range of GCP accountability requirements: receiving and logging the product, maintaining temperature monitoring records, completing the drug accountability log for every dispensing event, managing returns and reconciliation, and preserving all documentation for the required retention period. All of these obligations are detailed in our dedicated post on investigational medicinal product management.
When a product is classified as a NIMP or AxMP, the accountability requirements are generally lighter, though the protocol and sponsor’s pharmacy manual will specify exactly what documentation the site is expected to maintain. Sites should never assume that a NIMP requires no documentation whatsoever; the sponsor’s instructions govern what records must be kept, and these must be followed regardless of the product’s AxMP status.
For investigators new to the principal investigator role and seeking to understand how to set up and manage a compliant trial site, our practical guide on how to be a principal investigator and set up your clinical trial site provides a step-by-step overview of the operational requirements, including IP and NIMP management responsibilities.
All personnel involved in IMP or NIMP handling at a clinical trial site must be appropriately trained. This is a requirement under ICH GCP E6(R3), and training records must be available for review by monitors and inspectors. ICH GCP training that is compliant with the E6(R3) framework, such as the accredited program offered at PharmaEduCenter, ensures that site personnel have the knowledge they need to fulfill these obligations correctly. For an overview of what the fundamentals of clinical trials entail, our introductory post on the fundamentals of clinical trials is also a useful starting point for anyone joining a trial site team.
The ethics committee overseeing the trial must be informed of all medicinal products, both IMPs and AxMPs, used in the trial, as these are addressed in the protocol submitted for ethics review. For a full overview of the ethics committee’s role and its interface with the IMP and AxMP framework, see our guide to the essential roles of an ethics committee in clinical trials.
Key takeaways
- An IMP (investigational medicinal product) is the product being tested, used as a comparator, or used as a placebo in an EU clinical trial.
- A NIMP (non-investigational medicinal product) is a medicinal product used in the trial as specified in the protocol, but not as an IMP.
- Under the EU CTR 536/2014, the term NIMP has been formally replaced by AxMP (auxiliary medicinal product); the UK retains the NIMP terminology.
- The 5 critical differences between IMP and NIMP concern regulatory definition and legal basis, GMP and manufacturing requirements, CTIS registration and dossier requirements, labeling obligations, and pharmacovigilance and safety reporting.
- AxMPs are classified into four main categories: rescue medications, background treatment, challenge agents, and diagnostic/endpoint tools.
- Misclassification of an IMP as a NIMP (or vice versa) can result in regulatory findings, trial delays, and unanticipated costs.
- Authorized AxMPs used in their licensed, unmodified form carry the lightest regulatory requirements; unauthorized or modified AxMPs carry requirements approaching those of IMPs.
- All site personnel handling IMPs or AxMPs must be appropriately trained, with training documented and available for inspection.
- ICH GCP certification from an accredited provider such as PharmaEduCenter equips professionals to navigate the IMP vs NIMP distinction with confidence.
Conclusion
The distinction between an IMP and an NIMP is one of the foundational classification decisions in EU clinical trial design and operation. It determines the GMP controls, labeling requirements, CTIS documentation, and pharmacovigilance obligations that will apply to every medicinal product in the trial. The transition from the NIMP concept under the old Clinical Trials Directive to the AxMP concept under the EU CTR 536/2014 has brought greater regulatory precision, but also new terminology to navigate, particularly for teams running trials across both EU and UK sites.
Whether you are a sponsor’s regulatory affairs professional classifying trial products during protocol development, an investigator reviewing the pharmacy manual at site initiation, or a CRA verifying accountability records during a monitoring visit, understanding the IMP vs NIMP (AxMP) distinction and its practical implications is not optional; it is a core GCP competency.
The most effective way to build and maintain that competency is through structured, accredited Good Clinical Practice training that is current with the ICH GCP E6(R3) framework and the EU CTR requirements.
Is your team ready to master IMP management, NIMP classification, and every other key requirement of ICH GCP E6(R3)?
PharmaEduCenter’s ICH GCP training and certification program is accredited by the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom and recognized by TransCelerate BioPharma as meeting the criteria for ICH GCP Investigator Site Personnel Training. Whether you need a full ICH GCP certification or a focused Good Clinical Practice training for investigators, we have a program designed for your role. Start your training today.
FAQ: IMP vs NIMP in EU clinical trials
What is the difference between IMP and NIMP in clinical trials?
An IMP (investigational medicinal product) is the product being tested or used as a comparator or placebo in a clinical trial. A NIMP (non-investigational medicinal product) is a medicinal product used in the trial as specified in the protocol but not as the product under investigation. In the EU, the current term for NIMP under CTR 536/2014 is AxMP (auxiliary medicinal product).
What does NIMP stand for in clinical trials?
NIMP stands for non-investigational medicinal product. It refers to a medicinal product used in a clinical trial to support its conduct, such as a rescue medication, background treatment, or challenge agent, without itself being the product under investigation. In the EU, NIMPs are now formally called auxiliary medicinal products (AxMPs) under EU CTR 536/2014.
Is a placebo an IMP or a NIMP?
A placebo used as a control or comparator in a clinical trial is an IMP, not a NIMP. This is explicitly stated in the EU CTR 536/2014 definition: an IMP includes a medicinal product being tested or used as a reference, including as a placebo. Placebos are therefore subject to the same GMP, labeling, accountability, and pharmacovigilance requirements as other IMPs.
What is an auxiliary medicinal product (AxMP)?
An auxiliary medicinal product (AxMP), as defined in EU CTR 536/2014, is a medicinal product used for the needs of a clinical trial as described in the protocol, but not as an investigational medicinal product. The AxMP is the EU CTR successor to the NIMP concept used under the older Clinical Trials Directive 2001/20/EC.
Does an AxMP (NIMP) need to be registered in CTIS?
Yes. All AxMPs used in an EU clinical trial must be registered in CTIS and supported by an Auxiliary Medicinal Product Dossier (AxMPD). For authorized AxMPs used in their licensed, unmodified form, a simplified AxMPD is accepted. Unauthorized AxMPs require more detailed documentation and must also be registered in the XEVMPD database.
Are there GMP requirements for NIMPs (AxMPs)?
Yes. Under both the EU CTR 536/2014 and the UK clinical trials regulations, all NIMPs (or AxMPs) must be manufactured or assembled in accordance with applicable GMP principles. For authorized products used without modification, their existing manufacturing authorization is generally sufficient evidence of GMP compliance. For unauthorized or modified NIMPs, more formal GMP documentation is required.
Is an AxMP subject to SUSAR reporting?
Authorized AxMPs used within their licensed indications are generally not subject to expedited SUSAR reporting obligations. Adverse reactions to authorized AxMPs are managed through post-marketing pharmacovigilance channels. However, where an adverse event’s cause is uncertain between the IMP and an AxMP, a cautious approach to reporting is expected. Unauthorized AxMPs may carry reporting requirements closer to those applicable to IMPs, and this should be addressed in the trial’s pharmacovigilance plan.
Why does the UK still use NIMP while the EU uses AxMP?
Following Brexit, the UK did not adopt EU CTR 536/2014 and instead updated its own clinical trials legislation independently. The UK Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 retained the NIMP terminology rather than adopting the EU’s AxMP designation. The underlying regulatory concept is the same; only the terminology differs, which is particularly relevant for sponsors running multinational trials across both EU and UK sites.
